Eads & Heald Wealth Management Has $1 Million Position in Bristol Myers Squibb Company $BMY

Eads & Heald Wealth Management boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 12.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,659 shares of the biopharmaceutical company’s stock after buying an additional 2,482 shares during the quarter. Eads & Heald Wealth Management’s holdings in Bristol Myers Squibb were worth $1,003,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. IVC Wealth Advisors LLC boosted its holdings in Bristol Myers Squibb by 15.5% during the second quarter. IVC Wealth Advisors LLC now owns 5,505 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 738 shares during the last quarter. Simplicity Wealth LLC boosted its stake in shares of Bristol Myers Squibb by 127.7% during the 2nd quarter. Simplicity Wealth LLC now owns 9,908 shares of the biopharmaceutical company’s stock worth $459,000 after buying an additional 5,556 shares during the last quarter. OLD National Bancorp IN grew its holdings in shares of Bristol Myers Squibb by 3.6% in the 2nd quarter. OLD National Bancorp IN now owns 204,028 shares of the biopharmaceutical company’s stock valued at $9,444,000 after acquiring an additional 7,136 shares in the last quarter. Capital City Trust Co. FL increased its position in shares of Bristol Myers Squibb by 10.4% in the second quarter. Capital City Trust Co. FL now owns 22,082 shares of the biopharmaceutical company’s stock valued at $1,022,000 after acquiring an additional 2,088 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC raised its holdings in Bristol Myers Squibb by 1.2% during the second quarter. Wealthcare Advisory Partners LLC now owns 47,473 shares of the biopharmaceutical company’s stock worth $2,198,000 after acquiring an additional 546 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $45.39 on Monday. The firm has a market cap of $92.38 billion, a P/E ratio of 18.30, a price-to-earnings-growth ratio of 2.32 and a beta of 0.33. The business’s 50 day moving average is $46.36 and its 200-day moving average is $48.49. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the prior year, the firm posted $2.07 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb’s payout ratio is 100.00%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BMY shares. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Saturday, September 27th. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Citigroup cut their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.